Pancreatic Cancer Detection Consortium
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona histologicznie diagnoza raka trzustki (stopnie I-IV)
- •Przeprowadzenie standardowych badań diagnostycznych przed rozpoczęciem leczenia
- •Pobranie próbki krwi przed leczeniem
✗ Disqualifies
- •Brak pisemnej zgody na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (11)
Translational Genomics Research Institute
Phoenix, United States
Honorhealth
Scottsdale, United States
City of Hope Medical Center
Monrovia, United States
Hoag Center
Newport Beach, United States
OSF HealthCare
Peoria, United States
Ochsner Medical Center
Jefferson, United States
Atlantic Health System
Morristown, United States
Piedmont Medical Center
Rock Hill, United States
Medical College of Wisconsin
Milwaukee, United States
Nagoya University
Nagoya, Japan
Asan Medical Center
Seoul, South Korea
Trial contact
Ajay Goel, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.